GlassScriptPhysician profile
William Joe Helwig
NPI 1275533564
$1,537.91
in general payments reported to CMS, 2019-2025
23 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $23.37 · 2021: $62.46 · 2022: $334 · 2023: $325 · 2024: $309 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $254.30 | 2022-2024 | Cimzia, Bimzelx |
| Oyster Point Pharma, INC. | $191.87 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $169.30 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $162.42 | 2019-2024 | Cequa |
| Allergan, INC. | $122.27 | 2019 | |
| Bausch & Lomb Americas INC. | $120.03 | 2023-2025 | Miebo, Vyzulta, Prolensa |
| Dompe US, INC. | $61.79 | 2024-2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $60.56 | 2021-2025 | Dupixent |
| Alcon Vision LLC | $52.04 | 2022-2025 | Tryptyr |
| Tarsus Pharmaceuticals, INC. | $50.57 | 2025 | Xdemvy |
| Harrow Eye, LLC | $45.40 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $37.88 | 2025 | |
| Leo Pharma INC. | $33.51 | 2022 | |
| Fresenius Kabi USA, LLC | $33.10 | 2023-2024 | Idacio |
| Mallinckrodt Hospital Products INC. | $24.78 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $21.14 | 2021 | |
| Incyte Corporation | $18.90 | 2023 | Opzelura |
| Verrica Pharmaceuticals INC. | $14.39 | 2023 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.36 | 2022 | |
| Janssen Biotech, INC. | $14.35 | 2025 | Tremfya |
| Shire North American Group INC | $12.59 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.23 | 2019 | |
| Kala Pharmaceuticals, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Helwig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.